Company Filing History:
Years Active: 2006
Title: Anil Bajpai: Innovator in Gene Therapy
Introduction: Anil Bajpai is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of gene therapy, particularly through his research on adeno-associated viruses (AAV). His work focuses on understanding the mechanisms that influence transgene expression, which is crucial for advancing gene therapy techniques.
Latest Patents: Anil Bajpai holds a patent titled "Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression." This invention identifies a protein known as the D-sequence-binding protein (D-BP), which is phosphorylated at tyrosine residues. The D-BP inhibits AAV-mediated transgene expression in infected cells by blocking the leading strand viral DNA synthesis. The patent also reveals that D-BP is phosphorylated by EGF-R protein tyrosine kinase. Furthermore, it discloses methods for increasing transcription and promoting replication of transgenes by utilizing this information.
Career Highlights: Anil Bajpai is associated with the Advanced Research & Technology Institute, where he continues to explore innovative solutions in gene therapy. His research has the potential to enhance the effectiveness of gene therapies, making them more viable for clinical applications.
Collaborations: Anil has collaborated with esteemed colleagues such as Arun Srivastava and Keyun Qing, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion: Anil Bajpai's work exemplifies the intersection of innovation and biotechnology, particularly in the realm of gene therapy. His contributions through patents and collaborations are paving the way for advancements that could significantly impact medical science.